Chromocell Therapeutics Corporation (CHRO)
- GlobeNewswire
Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its CEO Frank Knuettel, will be presenting at Alliance Global Partners Healthcare Company Showcase on Tuesday, May 21, 2024. The conference provides Alliance Global Partners’ top healthcare companies with an opportunity to discuss what they think are important indu
- GlobeNewswire
Chromocell Issues Letter to Stockholders from Chief Executive Officer
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its Chief Executive Officer, Frank Knuettel, has issued the following letter to stockholders: Dear Fellow Stockholders, With my inaugural letter to stockholders, I am pleased to provide an update on our recent initial public offering (“IPO”), share our mission, o
- GlobeNewswire
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
New Program Targets Estimated $2.5 Billion Eye Pain MarketFREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler. The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications. Commo
